Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lificiguat (YC-1) 是一种不依赖一氧化氮的可溶性鸟苷酸环化酶激活剂和低氧诱导因子 1α 的抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 287 | 现货 | ||
5 mg | ¥ 455 | 现货 | ||
10 mg | ¥ 638 | 现货 | ||
25 mg | ¥ 1,250 | 现货 | ||
50 mg | ¥ 2,320 | 现货 | ||
100 mg | ¥ 3,490 | 现货 | ||
200 mg | ¥ 4,960 | 现货 | ||
500 mg | ¥ 7,890 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 490 | 现货 |
产品描述 | Lificiguat (YC-1) is an nitric oxide (NO)-independent activator of soluble guanylyl cyclase(sGC) and an inhibitor of Hypoxia-inducible factor-1alpha (HIF-1alpha). |
靶点活性 | sGC (presence of CO):0.6-1.1 μM (Kd) |
体外活性 | YC-1 increases the catalytic rate of the soluble guanylyl cyclase (sGC) and sensitizes the enzyme toward its gaseous activators nitric oxide or carbon monoxide. YC-1 alone activates the enzyme only 10-fold, but it potentiates the CO- and NO-dependent activation of sGC, resulting in stimulation of the highly purified enzyme that may be several hundred- to several thousand-fold. It inhibits platelet aggregation and vascular contraction and also inhibits HIF-1 activity in vitro. YC-1 completely blocks HIF-1α expression at the post-transcriptional level and consequently inhibits the transcription factor activity of HIF-1 in hepatoma cells cultured under hypoxic conditions, suggesting that these effects of YC-1 are likely to be linked with the oxygen-sensing pathway and not with the activation of soluble guanylyl cyclase. |
体内活性 | In experimental animals, YC-1 causes the inhibition of the platelet-rich thrombosis and a decrease of the mean arterial pressure. YC-1 effectively inhibits tumor growth in tumor-bearing mice. In mice, YC-1 inhibition of HIF-1 activity in tumors, and this is associated with blocked angiogenesis and an inhibition of tumor growth, while the anti-platelet aggregation effect of YC-1 does not appear to affect tumor growth. |
细胞实验 | Hep3B cells are plated in a six-well plate at a density of 1 × 105 cells/well in α-modified Eagle medium supplemented with 10% heat-inactivated FBS and incubated overnight. Cells are treated with YC-1 (0.01-10 μM) or vehicle (DMSO) for 5 minutes and are then subjected to normoxia or hypoxia for 24 hours. VEGF levels in the conditioned media are quantified by using the Quantikine human VEGF Immunoassay kit. The VEGF concentrations are quantified by comparison with a series of VEGF standard samples included in the assay kit. |
动物实验 | Animal Models: Male nude (BALB/cAnNCrj–nu/nu) mice. Formulation: DMSO. Dosages: 30 μg/g. Administration: i.p. |
别名 | 利非西呱, YC-1 |
分子量 | 304.34 |
分子式 | C19H16N2O2 |
CAS No. | 170632-47-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30.4 mg/mL(100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.2858 mL | 16.429 mL | 32.858 mL | 82.145 mL |
5 mM | 0.6572 mL | 3.2858 mL | 6.5716 mL | 16.429 mL | |
10 mM | 0.3286 mL | 1.6429 mL | 3.2858 mL | 8.2145 mL | |
20 mM | 0.1643 mL | 0.8214 mL | 1.6429 mL | 4.1072 mL | |
50 mM | 0.0657 mL | 0.3286 mL | 0.6572 mL | 1.6429 mL | |
100 mM | 0.0329 mL | 0.1643 mL | 0.3286 mL | 0.8214 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Lificiguat 170632-47-0 Angiogenesis Chromatin/Epigenetic GPCR/G Protein Others Guanylate cyclase HIF Guanylate Cyclase Inhibitor YC 1 利非西呱 YC-1 YC1 inhibit inhibitor